Akebia Therapeutics Reports First Quarter 2019 Financial Results; Announces Full Enrollment of Phase 3 INNO2VATE Studies and Announces Key Executive Appointments
Go back to Akebia Therapeutics Reports First Quarter 2019 Financial Results; Announces Full Enrollment of Phase 3 INNO2VATE Studies and Announces Key Executive Appointments| AKEBIA THERAPEUTICS (NASDAQ: AKBA) | Delayed: 0.92 -0.01 (1.08%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.93 | 52 Week High | $13.20 | |||
| Open | $0.92 | 52 Week Low | $7.00 | |||
| Day High | $0.95 | P/E | N/A | |||
| Day Low | $0.91 | EPS | $0.00 | |||
| Volume | 3,729,930 | |||||
